A-Elbasit Ishraga E, Elbashir Mustafa I, Khalil Insaf F, Alifrangis Michael, Giha Hayder A
Malaria Research Centre, Department of Biochemistry, University of Khartoum, Khartoum, Sudan.
Trop Med Int Health. 2006 May;11(5):604-12. doi: 10.1111/j.1365-3156.2006.01616.x.
To compare the efficacy of sulfadoxine-pyremethamine (SP)+chloroquine (CQ) combination treatment against falciparum malaria with SP treatment alone.
In-vivo study of 254 patients with uncomplicated Plasmodium falciparum malaria in rural eastern Sudan, where the population is semi-immune.
Sulfadoxine-pyremethamine treatment alone cured 68.3% (41/60) and SP+CQ cured 63.4% (123/194). Early and late treatment failures occurred in both treatment groups. Host age (as a marker for immunity) and parasite gametocytogenesis (as a marker for transmissibility) were significantly associated with SP resistance. Patients who were cured were significantly older (median age 21 years) than patients whose treatment failed (median age 12 years). Gametocyte production was significantly higher in patients with treatment failure (0.72 vs 0.45) and associated with younger age. Gametocyte counts were comparable between both groups until day 7 of follow up; thereafter, they were significantly higher in patients with treatment failure. However, the longevity of gametocytes was comparable in both treatment groups.
Chloroquine did not improve the parasite response to SP. Age was strongly associated with clearance of SP-resistant parasites. The fast rise of SP resistance may partially be due to selection of SP resistant parasites and expansion of the resistant population through the gametocytogenic effect of SP.
比较周效磺胺-乙胺嘧啶(SP)+氯喹(CQ)联合治疗与单纯SP治疗恶性疟的疗效。
对苏丹东部农村地区254例非复杂性恶性疟患者进行体内研究,该地区人群具有半免疫性。
单纯周效磺胺-乙胺嘧啶治疗治愈率为68.3%(41/60),SP+CQ治疗治愈率为63.4%(123/194)。两个治疗组均出现早期和晚期治疗失败情况。宿主年龄(作为免疫标志物)和寄生虫配子体形成(作为传播性标志物)与SP耐药性显著相关。治愈患者的年龄(中位年龄21岁)显著高于治疗失败患者(中位年龄12岁)。治疗失败患者的配子体产生显著更高(0.72对0.45),且与年龄较小相关。两组在随访第7天前配子体计数相当;此后,治疗失败患者的配子体计数显著更高。然而,两个治疗组中配子体的存活期相当。
氯喹未改善寄生虫对SP的反应。年龄与SP耐药寄生虫的清除密切相关。SP耐药性的快速上升可能部分归因于对SP耐药寄生虫的选择以及通过SP的配子体形成效应导致耐药群体的扩大。